News & Analysis on Clinical Trial Services & Contract Research And Development
Sanofi-Aventis' hotly touted anti-obesity blockbuster drug has become weighted down in safety concerns as the French company withdraws its New Drug Application (NDA) in the US and awaits a safety review in the EU.
A new and improved extended-release treatment for schizophrenia has been granted marketing authorisation by the European Commission. Invega (paliperidone) is a once-daily formulation that will be marketed by J&J subsidiary, Janssen-Cilag.
AstraZeneca has sold a manufacturing plant in France to a contract manufacturer who will continue to supply the drug giant with its products under a new outsourcing contract.
One of the most significant deals to take place in the vaccine industry in the last ten years was signed late last night between vaccine heavyweight Novartis and biotech firm Intercell.
Outsourcing-Pharma.com compiles the news that featured in the clinical contract community this past week, involving Encorium, Amarex, Paragon Biomedical, Pacific Biometrics and Parexel.
VASTox has managed to secure three pilot screening service deals with big pharma firms in the hope of impressing them with its zebrafish technology.
The finishing touches are being added to the new Bradman Lake Group's packaging machinery facility in Norwich, Norfolk, as the company continues on its global expansion plan.